DK1149589T3 - Proteinadjuvanser - Google Patents

Proteinadjuvanser

Info

Publication number
DK1149589T3
DK1149589T3 DK01201610T DK01201610T DK1149589T3 DK 1149589 T3 DK1149589 T3 DK 1149589T3 DK 01201610 T DK01201610 T DK 01201610T DK 01201610 T DK01201610 T DK 01201610T DK 1149589 T3 DK1149589 T3 DK 1149589T3
Authority
DK
Denmark
Prior art keywords
immune response
modulated immune
alum
genetically
antigen
Prior art date
Application number
DK01201610T
Other languages
English (en)
Inventor
Michel H Klein
Diane M Gajewczyk
Heather A Boux
Anton Novak
Original Assignee
Sanofi Pasteur Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22979642&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK1149589(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sanofi Pasteur Ltd filed Critical Sanofi Pasteur Ltd
Application granted granted Critical
Publication of DK1149589T3 publication Critical patent/DK1149589T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/099—Bordetella
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55516—Proteins; Peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55544—Bacterial toxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
DK01201610T 1994-06-10 1995-06-08 Proteinadjuvanser DK1149589T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US25822894A 1994-06-10 1994-06-10
PCT/CA1995/000341 WO1995034323A2 (en) 1994-06-10 1995-06-08 Proteinaceous adjuvants

Publications (1)

Publication Number Publication Date
DK1149589T3 true DK1149589T3 (da) 2009-08-17

Family

ID=22979642

Family Applications (2)

Application Number Title Priority Date Filing Date
DK95924122T DK0764029T4 (da) 1994-06-10 1995-06-08 Proteinadjuvanser
DK01201610T DK1149589T3 (da) 1994-06-10 1995-06-08 Proteinadjuvanser

Family Applications Before (1)

Application Number Title Priority Date Filing Date
DK95924122T DK0764029T4 (da) 1994-06-10 1995-06-08 Proteinadjuvanser

Country Status (10)

Country Link
US (2) US20030072774A1 (da)
EP (3) EP1149588A1 (da)
AT (2) ATE429928T1 (da)
AU (1) AU2876595A (da)
CA (1) CA2192454A1 (da)
DE (2) DE69535943D1 (da)
DK (2) DK0764029T4 (da)
ES (2) ES2179105T5 (da)
PT (2) PT764029E (da)
WO (1) WO1995034323A2 (da)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9513371D0 (en) 1995-06-30 1995-09-06 Biocine Spa Immunogenic detoxified mutant toxins
DK0725653T3 (da) 1993-10-05 2004-10-11 Celltech Pharmaceuticals Ltd Vaccinepræparater
GB9326174D0 (en) * 1993-12-22 1994-02-23 Biocine Sclavo Mucosal adjuvant
US20030072774A1 (en) * 1994-06-10 2003-04-17 Diane M. Gajewczyk Proteinaceous adjuvants
GB9500788D0 (en) * 1995-01-16 1995-03-08 Medeva Holdings Bv Vaccine compositions
US6020182A (en) 1996-07-12 2000-02-01 Connaught Laboratories Limited Subunit respiratory syncytial virus vaccine preparation
GB9622660D0 (en) 1996-10-31 1997-01-08 Biocine Spa Immunogenic detoxified mutant toxin
EP1486215A3 (en) * 1997-03-21 2006-04-12 Chiron Corporation Detoxified mutants of bacterial ADP-ribosylating toxins as parenteral adjuvants
US6818222B1 (en) 1997-03-21 2004-11-16 Chiron Corporation Detoxified mutants of bacterial ADP-ribosylating toxins as parenteral adjuvants
JP4530317B2 (ja) * 1998-10-21 2010-08-25 学校法人北里研究所 減毒化トキシンを含むワクチン製剤
WO2000035481A2 (en) 1998-12-17 2000-06-22 Connaught Laboratories Limited Multivalent immunogenic composition containing rsv subunit composition and influenza virus preparation
US7115730B1 (en) 1999-04-27 2006-10-03 Chiron Srl Immunogenic detoxified mutant E. coli LT-A-toxin
CA2721011A1 (en) 1999-10-22 2001-05-03 Aventis Pasteur Limited Modified gp100 and uses thereof
EP1792995A3 (en) 2000-05-08 2007-06-13 Sanofi Pasteur Limited Chlamydia secretory locus orf and uses thereof
WO2001085932A2 (en) 2000-05-10 2001-11-15 Aventis Pasteur Limited Immunogenic polypeptides encoded by mage minigenes and uses thereof
AU2001285633A1 (en) 2000-08-25 2002-03-04 Aventis Pasteur Limited Haemophilus influenzae lipopolysaccharide inner-core oligosaccharide epitopes as vaccines for the prevention of haemophilus influenzae infections
EP1404368B1 (en) 2001-06-07 2009-12-09 Wyeth Holdings Corporation Mutant forms of cholera holotoxin as an adjuvant
KR20080078717A (ko) * 2001-06-07 2008-08-27 와이어쓰 홀딩스 코포레이션 보조제로서 콜레라 홀로톡신의 돌연변이체 형태
DK2495327T3 (da) 2006-03-03 2017-01-02 Promis Neurosciences Inc Fremgangsmåder og sammensætninger til at behandle og opdage sygdomme fremkaldt af fejlfoldet SOD1
BRPI0721702A2 (pt) 2007-05-23 2013-01-15 Uab Research Foundation neuraminidase pneumocàcica destoxificada ou uma porÇço antigÊnica da mesma, composiÇço, mÉtodos para reduzir ou prevenir a portabilidade nasal pneumocàcica em um indivÍduo, e para reduzir ou prevenir a infecÇço pneumocàcica em um indivÍduo, e, recipiente
AU2008299536B2 (en) 2007-09-11 2014-06-12 University Of Guelph Novel polysaccharide immunogens from clostridium difficile
WO2009039125A1 (en) * 2007-09-17 2009-03-26 The Schepens Eye Research Institute, Inc. Use of ocular neuropeptides as immune adjuvants
US8210944B2 (en) * 2007-10-29 2012-07-03 Igt Gaming system having display device with changeable wheel
JP5070006B2 (ja) * 2007-11-02 2012-11-07 株式会社オハラ 結晶化ガラス
KR101741426B1 (ko) 2008-12-24 2017-05-30 더 킹덤 오드 더 네덜란드, 레프리젠티드 바이 더 미니스트리 오브 헬스, 웰페어 앤드 스포츠, 온 비하프 오브 더 미니스터, 더 내셔널 인스티튜트 포 퍼블릭 헬스 앤드 디 인바이런먼트 변형된 스트렙토코커스 뉴모니아 뉴몰리신(ｐｌｙ) 폴리펩타이드
EP2668201A2 (en) 2011-01-28 2013-12-04 Sanofi Pasteur SA Immunological compositions comprising hiv gp41 polypeptide derivatives
ES2642138T3 (es) * 2011-12-21 2017-11-15 Bionet-Asia Co. Ltd Cepas de Bordetella pertussis modificadas
WO2014140938A2 (en) 2013-03-14 2014-09-18 Centre Hospitalier Universitaire Vaudois Immunological methods
US10774120B2 (en) 2015-11-09 2020-09-15 The University Of British Columbia Anti-amyloid beta antibodies binding to a cyclic amyloid beta peptide
KR20180088828A (ko) 2015-11-09 2018-08-07 더 유니버시티 오브 브리티쉬 콜롬비아 아밀로이드 베타에서의 n-말단 에피토프 및 이에 형태적으로-선택적인 항체
US10759837B2 (en) 2015-11-09 2020-09-01 The University Of British Columbia Anti-amyloid beta antibodies binding to a cyclic amyloid beta peptide
CA3031135A1 (en) 2016-07-18 2018-01-25 The University Of British Columbia Antibodies to amyloid beta
US20180125920A1 (en) 2016-11-09 2018-05-10 The University Of British Columbia Methods for preventing and treating A-beta oligomer-associated and/or -induced diseases and conditions
IT201900007060A1 (it) 2019-05-21 2020-11-21 St Superiore Di Sanita Cellule tumorali ingegnerizzate e loro usi
IT201900012540A1 (it) 2019-07-22 2021-01-22 Humanitas Mirasole Spa Inibitori di CHI3L1 e loro usi

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2144129B (en) * 1981-08-24 1985-10-09 Vilas V Likhite Antigens as immunostimulant adjuvants
KR0168039B1 (ko) * 1987-09-04 1999-01-15 로버트 디. 웨스트 재조합 dna에서 유도한 보르데텔라 외독소 소단위체의 유사체 및 그를 포함하는 백신
US5244657A (en) * 1987-11-24 1993-09-14 Connaught Laboratories Limited Genetic detoxification of pertussis toxin
GB8727489D0 (en) 1987-11-24 1987-12-23 Connaught Lab Detoxification of pertussis toxin
US5332583A (en) * 1987-11-24 1994-07-26 Connaught Laboratories Limited Vaccine containing genetically-detoxified pertussis holotoxin
US5358868A (en) * 1987-11-24 1994-10-25 Connaught Laboratories Limited Genetic detoxification of pertussis toxin
US5221618A (en) 1987-11-24 1993-06-22 Connaught Laboratories Limited Genetic detoxification of pertussis toxin
JP2849632B2 (ja) 1988-04-08 1999-01-20 社団法人北里研究所 ワクチン製剤
AP8900132A0 (en) * 1988-07-22 1991-01-14 Smithkline Biolog Bordetella pertussis vaccine
JPH03135923A (ja) * 1989-10-20 1991-06-10 Chemo Sero Therapeut Res Inst 百日咳毒素ｂオリゴマーの構成サブユニットを含有する経鼻接種ワクチン
US5786189A (en) * 1989-11-29 1998-07-28 Smithkline Beecham Biologicals (S.A.) Vaccine
IT1248735B (it) * 1990-06-21 1995-01-26 Sclavo Spa Vaccini acellulari contro la pertosse
DK0725653T3 (da) * 1993-10-05 2004-10-11 Celltech Pharmaceuticals Ltd Vaccinepræparater
US20030072774A1 (en) * 1994-06-10 2003-04-17 Diane M. Gajewczyk Proteinaceous adjuvants
US5932714A (en) * 1995-02-23 1999-08-03 Connaught Laboratories Limited Expression of gene products from genetically manipulated strains of Bordetella
JPH11121079A (ja) * 1997-10-20 1999-04-30 Yazaki Corp 圧接コネクタ及び圧接コネクタの組立方法
US7063852B2 (en) * 2000-05-19 2006-06-20 The Administrators Of The Tulane Educational Fund Hybrid LT-A/CT-B holotoxin for use as an adjuvant
GB0118249D0 (en) * 2001-07-26 2001-09-19 Chiron Spa Histidine vaccines
EP1575479A4 (en) * 2002-01-31 2006-10-25 Develogen Israel Ltd HSP-PEPTIDES AND ANALOGUES FOR MODULATING IMMUNE RESPONSES ON ANY PRESENTING CELLS
US6861410B1 (en) * 2002-03-21 2005-03-01 Chiron Corporation Immunological adjuvant compositions

Also Published As

Publication number Publication date
DE69527202D1 (de) 2002-08-01
WO1995034323A2 (en) 1995-12-21
EP0764029A1 (en) 1997-03-26
DE69527202T3 (de) 2008-07-31
EP0764029B1 (en) 2002-06-26
DE69535943D1 (de) 2009-06-10
EP1149588A1 (en) 2001-10-31
WO1995034323A3 (en) 1996-01-18
CA2192454A1 (en) 1995-12-21
EP0764029B2 (en) 2008-03-26
PT764029E (pt) 2002-10-31
ATE429928T1 (de) 2009-05-15
EP1149589B1 (en) 2009-04-29
EP1149589A1 (en) 2001-10-31
US20030072774A1 (en) 2003-04-17
AU2876595A (en) 1996-01-05
DE69527202T2 (de) 2002-12-05
ATE219686T1 (de) 2002-07-15
ES2179105T5 (es) 2008-06-16
ES2179105T3 (es) 2003-01-16
ES2325475T3 (es) 2009-09-07
US7105161B1 (en) 2006-09-12
DK0764029T4 (da) 2008-07-28
PT1149589E (pt) 2009-07-28
DK0764029T3 (da) 2002-10-21

Similar Documents

Publication Publication Date Title
DK0764029T3 (da) Proteinadjuvanser
IS4518A (is) Nýtt lyfjaform fyrir bóluefni
UY26801A1 (es) Composición de vacuna
ATE529130T1 (de) Trockenformulierung für transkutane immunisierung
DK1459766T3 (da) Adjuvanssammensætninger til forstærkning af immunresponser på polynukleotidbaserede vacciner
FI970799A0 (fi) Mutanttientoroksiini, joka on tehokas ei-toksinen oraalinen adjuvantti
AU3526995A (en) Vaccine compositions
NZ323973A (en) Vaccine compositions for intranasal administration comprising chitosan and use thereof
DK0625053T3 (da) Urease-baseret vaccine mod Helicobacter-infektion
LU91154I2 (fr) Combinaison d'anatoxine diphtérique, d'anatoxine tétanique, d'anatoxine coquelucheuse, d'hémagglutinine filamenteuse, de pertactine, de virus poliomyélitiqu inactivé type 1, type 2 et type 3 et de polyoside capsulaire d'Haemophilus influenzae type b.
BR0111834A (pt) Composições adjuvante e imunogênica, e, método para eliciar uma resposta imune a um antìgeno
NO972219D0 (no) Immunogenpreparater
NO924271L (no) Vaksiner med forbedret immunogenisitet
DK0636030T3 (da) Pasteurella haemolytica type A-1-bacterin-toxoid-vaccine
EP2116257A3 (en) Parenteral vaccine formulations and uses thereof
DE69228063D1 (de) Abgeschwächter rückmutierter virusimpfstoff gegen mareks krankheit serotyp-1